CN100364601C - Chinese traditional medicine composition for treating diabetic nephropathy - Google Patents
Chinese traditional medicine composition for treating diabetic nephropathy Download PDFInfo
- Publication number
- CN100364601C CN100364601C CNB200410064899XA CN200410064899A CN100364601C CN 100364601 C CN100364601 C CN 100364601C CN B200410064899X A CNB200410064899X A CN B200410064899XA CN 200410064899 A CN200410064899 A CN 200410064899A CN 100364601 C CN100364601 C CN 100364601C
- Authority
- CN
- China
- Prior art keywords
- radix
- rhizoma
- grams
- group
- chinese medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to a Chinese traditional medicine composition for curing diabetic nephropathy, which comprises 15 to 45g of raw astragalus root, 10 to 20g of radix aconiti lateralis preparata and 10 to 20 g of prepared rhubarb. The optimization proportion of the raw materials is 30g of astragalus root, 15g of radix aconiti lateralis preparata and 15g of prepared rhubarb. The scheme can be directly used for the production of traditional Chinese medicine for curing diabetic nephropathy, and other drugs can also be added. For example, one of notoginseng, danshen root, achyranthes bidentata, etc. is added to compound a drug for promoting blood circulation for removing blood stasis; one of ginseng, heterophylly falsestarwort root, codonopsis pilosula, etc. is added to compound a tonic; one of poria, rhizoma smilacis glabrae, caulis akebiae, etc. is added to compound diuresis-promoting herbal medicine. The present invention has few tastes of drugs and large dosage of a single drug; a better clinical curative effect can be ensured, and the function mechanism of the present invention can be clarified; under the condition of the definite function mechanism, the site (group) of function is possibly clarified, and furthermore, effective monomers (group) are found. In 138 examples of a cure group, 8 examples are healed by clinic, 23 examples show effects, 41 examples are effective, 6 examples are ineffective, and the total effective rate reaches 92.3%. The cure group has significant differences from the control group.
Description
Technical field
The present invention relates to a kind of Chinese medicine composition for the treatment of diabetic nephropathy.
Background technology
Diabetic nephropathy (DN) is the diabetes most common complication, also is one of major causes of death of diabetics.Along with China's growth in the living standard, diabetes particularly type 2 diabetes mellitus sickness rate rise year by year, and the DN sickness rate is increases trend significantly year by year, and its total incidence rate is up to about 40%.
The DN cause of disease and pathogenesis are very complicated, remove foreign genetic element, also relate to all many-sides such as metabolism, hemodynamics, the relative growth factor, cytokine.The main pathological change of diabetic nephropathy is a mesangial cell stromatin excessive buildup, occurs glomerular sclerosis and renal tubules interstitial fibrosis afterwards.Domestic and international research all shows, transforming growth factor-beta
1(TGF-β
1) overexpression is the main cause that stromatin generate to increase and degraded reduces, TGF-β
1Be the pathogenetic final common pathway of DN, but concrete molecular mechanism it be unclear that.Discovering recently, Connective Tissue Growth Factor (CTGF) may participate in above-mentioned pathological process, and it is TGF-β
1High expressed causes the especially middle mediators of IV Collagen Type VI, Fibronectin and Laminin over-deposit of stromatin.
Think at present, divide three phases on the control principle of DN, the phase I is the prevention of DN: the patient is once being diagnosed as diabetes or finding impaired glucose tolerance (IGT), just answer active treatment, strict blood sugar control is corrected IGT state in the body, prevents microalbuminuria.Second stage be the early stage microalbuminuria that occurs of the early treatment of DN: DN behind active treatment, part patient can reverse.The treatment intervention in this stage can reduce and delay a large amount of albuminuretic generations.Renal insufficiency takes place and delays its progress for prevention DN patient in the phase III.Angle from evidence-based medicine EBM, no matter be multicenter, perspective, large sample, reach the clinical trial of contrast at random, or clinical research meta-analysis, the result shows: strict control hyperglycemia, hypertension and application angiotensin converting enzyme inhibitor and angiotensin ii receptor antagonist, especially in first and second stages of DN control, can significantly reduce the generation of DN and delay its disease progression.But people also notice, although taked above-mentioned related measure, still have part DN patient to can not get control, and the state of an illness is still carried out sexual development.And DN patient's renal insufficiency tempo is more faster than other renal disease patient.Obviously, further improve the level of preventing and treating of DN, must on the basis of existing treatment measure,, explore new treatment means, give multipath Comprehensive Treatment from the multiaction site at the multiple Developmental and Metabolic Disorder that diabetes itself exist.
Chinese medicine may relate to the Developmental and Metabolic Disorder of multiaction site protection kidney and reverting diabetes and improve clinical symptoms.In recent years, increasing about the report of treatment by Chinese herbs DN, mostly be clinical observation on the therapeutic effect and analysis greatly, its mechanisms of therapeutic action research report is very few, and big compound recipe (ten pleasant impressions, 20 pleasant impressions or more at most at least) is the observational study focus.Though big compound recipe has good and clinical curative effect, illustrating its therapeutical effect mechanism very is difficulty; Single medicinal material or monomer many places are in the experimental study stage, because its no drug matching advantage, so clinical efficacy is not ideal mostly.
Summary of the invention
The present invention tries hard under instruction of Chinese Medicine theory, as object of study, illustrates its site of action (group) with little compound recipe (Six-element medicine following) from different perspectives, and then seeks effective monomer (group), and this will be the main direction of Chinese medicine research from now on.The present invention is intended to tentatively to disclose Chinese medicine compound by clinical observation and experimentation and intervenes the hemodynamics mechanism of diabetic nephropathy kidney HT state and suppress renal cortex CTGF, TGF-β
1The The Molecular Biology Mechanism of mRNA high expressed state in the hope of illustrating its site of action (group), and then is sought effective monomer (group).This result of study not only helps to open up the new treatment approach of primary disease, enriches herbal pharmacology, can also lay good experiment basis for Chinese medicine goes to the world.
The technical scheme of finishing the foregoing invention task is: the Chinese medicine composition of treatment diabetic nephropathy comprises in the said composition:
Radix Astragali 15～45 grams, Radix Aconiti Lateralis Preparata 10～20 grams, Radix et Rhizoma Rhei (processed) 10～20 grams.
Following ratio is recommended in application:
Radix Astragali 30 grams, Radix Aconiti Lateralis Preparata 15 grams, Radix et Rhizoma Rhei (processed) 15 grams.
It is oral that this compound recipe can be made into capsule, electuary, oral liquid etc., every day above-mentioned dosage divide sooner or later twice oral.Above ratio is a dose.
Fang Yi:
The Radix Astragali: sweet, tepor, nontoxic, effect; Invigorating the spleen and replenishing QI is supporing yang, nourshing blood and promoting blood circulation, inducing diuresis to remove edema, eliminating the toxic material out by tonification.
Radix Aconiti Lateralis Preparata: suffering, sweet, heat, poisonous, effect; Recuperating depleted YANG and rescuing the patient from collapse, warming YANG to promote diuresis, removing blood stasis with potent drugs removing food stagnancy.
Radix Et Rhizoma Rhei: hardship, cold, mild toxicity, effect; Stasis removing, clearing away heat,cooling blood and removing toxin, blood circulation promoting and blood stasis dispelling.
The Radix Astragali is joined Radix Aconiti Lateralis Preparata QI invigorating warming the interior, nourishing YIN for harmonizing YANG, and activating YANG for promoting diuresis is got its Yin grows while yang is generating, the justice of QI invigorating (sun) row water; Radix Aconiti Lateralis Preparata helps Radix Et Rhizoma Rhei to cleanse dirt, pushes away Chen Zhixin, and Radix Et Rhizoma Rhei restricts Radix Aconiti Lateralis Preparata first in case second its overheated impairment of YIN helps Radix Aconiti Lateralis Preparata, the Radix Astragali to divide the purpose that disappears before and after reaching; Three medicines share and gather the tonifying YIN that activates yang altogether, promote the circulation of qi and water, and purging FU-organs rushes down turbid, the merit of blood circulation promoting and blood stasis dispelling.
Modern pharmacological research:
The Radix Astragali:
Chemical constituent: main component is astragalin unit and astragalus polysaccharides.
Pharmacological action: clinical research shows that the single medicinal material Radix Astragali not only can improve DN patient's clinical symptoms, and can reverse part patient's pathological change.Mainly by following mechanism: 1. reduce patient's blood pressure, reduce blood, urine β
2-microglobulin reduces urinary albumin excretion and plasma fibrin unit level.2. inhibited oxidation reaction, microcirculation improvement.3. minimizing endothelial cell damage.
Radix Et Rhizoma Rhei:
Chemical constituent: main component is Radix Et Rhizoma Rhei anthraquinone, chrysophanic acid and rhababerone.
Pharmacological action: clinical research shows that the single Radix Et Rhizoma Rhei also can partly improve DN patient's clinical symptoms.
Mainly by following mechanism: 1. reduce DN patient's urinary protein excretion rate, improve renal function and hemodynamic index.2. alleviate the kidney hypertrophy, dwindle glomerule area and mesangial region area.3. reduce the glomerule transforming growth factor-beta
1And the expression of glucose transporter 1mRNA.
Radix Aconiti Lateralis Preparata:
Chemical constituent: main component monoesters Alkaloid and coryneine.
Pharmacological action: the single Radix Aconiti Lateralis Preparata is used for the treatment of DN and does not appear in the newspapers as yet, is used in the compound recipe more.It uses following pharmacological action: 1. there is excitation in pair HPA system.2. can improve human body to anoxybiotic tolerance.3. to the kidney protective effect of experimental nephritis.
Above scheme can be directly used in the Chinese medicine production of treatment diabetic nephropathy, but also can increase the other medicines component on the basis of this basic scheme, constitutes prioritization scheme, for example:
Compatibility drug for invigorating blood circulation and eliminating stasis: a kind of in Radix Notoginseng, Radix Salviae Miltiorrhizae, Radix Achyranthis Bidentatae, Rhizoma Chuanxiong, Semen Persicae, Flos Carthami, Semen Vaccariae, Squama Manis, Herba Lycopi, Herba Leonuri, Olibanum, Myrrha, Spina Gleditsiae, Rhizoma Curcumae Longae, Rhizoma Curcumae, rhizoma sparganic, the Ramulus Euonymi (Herba Buchnerae cruciatae) etc.
Compatibility tonic: a kind of in Radix Ginseng, Radix Pseudostellariae, Radix Codonopsis, Radix Adenophorae (Radix Glehniae), Radix Angelicae Sinensis, Rhizoma Dioscoreae, Seem Lablab Album, Radix Polygoni Multiflori, the Rhizoma Atractylodis Macrocephalae, Fructus Lycii, Rhizoma Polygonati, the Radix Rehmanniae etc.
Compatibility diuretic medicine: Poria, Rhizoma Smilacis Glabrae, Caulis Akebiae, Semen Plantaginis, Pericarpium Arecae, Folium Pyrrosiae, Semen Abutili, Semen Coicis,
Hold, a kind of in Polyporus, Herba Dianthi etc.
The consumption of above compatibe drug can be by the conventional amount used on the pharmacopeia.
This project is the research point of penetration with the tcm small compound prescription, systematically inquires into the mechanism of treatment by Chinese herbs diabetic nephropathy, has following advantage:
● medicine flavor number is few, and the single medicinal material consumption is big.
● promptly guarantee clinical efficacy preferably, can illustrate its mechanism of action again.
● under the clear and definite situation of the mechanism of action, might illustrate its site of action (group), and then seek effective monomer (group).
Zoopery: choosing body weight is the complete male SD rats of 180 ± 20 grams, and disposable celiac injection streptozotocin (STZ) 80mg/kg greater than 11.1mmol/L, is an inclusion criteria less than 25mmol/L with OGTT2h blood glucose.Diabetes rat is divided into diabetes model matched group, treatment by Chinese herbs group at random, irritates stomach, 12 weeks of time at 8 o'clock in morning every day.Other establishes the normal control group.The result is as follows:
Subordinate list: Chinese medicine composition is to the influence of DN rat mean arterial pressure and renal hemodynamics
| Group | Mean arterial pressure | Renal blood flow (RPF) | Glomerule was considered rate (GFR) |
| Normal group (n=9) DN matched group (n=7) treatment by Chinese herbs group (n=10) | 14.8±0.5 15.3±0.5 15.0±1.0 | 3.44±0.50 4.54±0.24 ** 3.92±0.15 ** | 0.94±0.03 1.15±0.04 ** 1.05±0.02 *** |
Annotate: with normal group than * P＜0.05; * P＜0.01, with the DN matched group than #P＜0.05
Above presentation of results: Chinese medicine compound can suppress the rising of renal blood flow, and this can improve the early stage kidney HT of DN and height was considered state.
Cell culture studies: adopt high sugar to cultivate Rat Mesangial pearl and drug serum preparation method.Be divided into conventional cultivation group (I), normal rat serum group (II), Chinese medicine low dose group (III), Chinese medicine high dose group (IV), the result is as follows:
Subordinate list 1: Chinese medicine compound is to the influence of mesangial cell (MC) with extracellular matrix (ECM) component content
| Group | n | Factor | MTT (OD value) | FN (OD value) | LN(ng/ml) | ColIV(μg/l) |
| I II III IV | 6 6 6 6 | -20% Mus serum 20%LC Mus serum 20%HC Mus serum | 1.63±0.14 1.57±0.12 1.31±0.05 *Δ 1.21±0.09 *Δ | 0.22±0.06 0.23±0.07 0.07±0.04 *Δ 0.11±0.02 *Δ | 79.6±7.3 85.1±7.5 52.4±3.1 *Δ 62.5±3.7 *Δ | 30.1±3.4 30.7±3.6 12.2±3.2 *Δ 18.99±6.2 *Δ |
Annotate: with the I ratio
*P＜0.01; With II than Δ P＜0.01
More than explanation: Chinese medicine compound has the mesangial cell of inhibition propagation and the excretory effect of mesangial cell substrate.
Subordinate list 2: Chinese medicine compound is cultivated mesangial cell secretion TGF-β to high sugar
1Influence
| Incubation time | n | TGF-β 1Content (OD value) | |
| Matched group | Chinese drug-treated group | ||
| 1 2 3 4 | 6 6 6 6 | 0.38±0.04 Δ 0.59±0.01 Δ 0.63±0.04 Δ 0.59±0.04 Δ | 0.23±0.02 0.22±0.02 0.22±0.05 0.23±0.05 |
Annotate: with Chinese drug-treated group than Δ P＜0.01
Above presentation of results: Chinese medicine compound has the mesangial cell of inhibition secretion TGF-β
1Effect.
Zoopery and cell culture result confirm in a word: the compound of Chinese medicine diabetic nephropathy be by its suppress early stage HT of DIN and high worry state and suppress mesangial cell propagation and suppress mesangial cell secretory cell substrate be used for realize.
Below in conjunction with the clinical experimental data of basic side and the animal data of three prioritization schemes, effect of the present invention is described further.
Clinical data
The diabetic nephropathy diagnostic criteria:
The diabetes diagnosis standard that meets in June, 1997 ADA, continuous 2-3 urinary albumin excretion rate (UAER)＞30mg/24h or 20ug/min in June simultaneously.Except other causes albuminuretic factor.
Include standard in
Meet above-mentioned diagnostic criteria Mogensen classification method II phase, III phase, IV phase patient.
Exclusion standard
1.Mogensen the classification method V phase, promptly whole latter stage renal failure, GFR＜10ml/min person.
2. merge other system's serious disease and psychotic.
3. gestation and women breast-feeding their children.
4. age＜18 year old were gone up the person in＞65 years old.
5. do not take medicine in accordance with regulations, interrupt midway, can't add up curative effect person.
Efficacy assessment standard
Clinical cure: the symptom and sign complete obiteration, 24h urine protein quantitation＜100mg, blood urea nitrogen (BUN), serum creatinine (Scr) are all reduced to normal level.
Produce effects: symptom and sign disappears substantially, 24h urine protein quantitation＜500mg, or more preceding decline is more than 2/3, and the more preceding decline of BUN, Scr is more than 1/3.
Effectively: symptom and sign alleviates, and all more preceding decline of 24h urine protein quantitation, BUN, Scr is more than 1/3.
Invalid: as not reach the effective standard or the person of increasing the weight of.
Therapeutic Method:
The treatment group: regular diet, motion, hypoglycemic drug, add just substantially, oral, every day 3 times, 3 months was 1 course of treatment, took 2 courses of treatment continuously.
Matched group: regular diet, motion, hypoglycemic drug, add placebo, every day 3 times, 3 months was 1 course of treatment, took 2 courses of treatment continuously.
The result:
138 routine patients are divided into treatment group and matched group at random.Treatment group clinical cure 8 examples, produce effects 23 examples, effective 41 examples, invalid 6 examples, total effective rate 92.3%; Matched group clinical cure 0 example, produce effects 6 examples, effective 31 examples, invalid 23 examples, total effective rate 61.7%; Two groups of total effective rates relatively have significant difference (P＜0.05).
Subordinate list: every index comparison before and after two groups of treatments (
)
| Group | Time | Urine protein (g/24h) | Serum creatinine (μ mol/L) | Blood urea nitrogen (mmol/L) | Cholesterol (mmol/L) | Triglyceride (mmol/L) |
| Treatment group (n=78) | Before the treatment | 1.62±0.44 | 192±6.03 | 9.02±1.35 | 7.59±0.72 | 7.59±0.72 |
| After the treatment | 0.41±0.13 | 103±5.32 | 5.37±1.17 | 6.53±0.66 | 2.53±0.76 | |
| Matched group (n=60) | Before the treatment | 1.58±0.49 | 189±5.01 | 8.92±1.65 | 7.30±0.82 | 2.18±0.83 |
| After the treatment | 1.31±0.29 | 141±4.73 | 7.02±1.32 | 7.04±0.69 | 1.98±0.76 |
Annotate: all there is significant difference (P is all＜0.05) compatibility different pharmaceutical zoopery correlation data treatment group front and back relatively urine protein quantitation, serum creatinine, essence nitrogen, cholesterol, triglyceride:
Three class medicines are chosen a kind of representative medicine respectively and are experimentized:
The compatibility drug for invigorating blood circulation and eliminating stasis: substantially just+Radix Notoginseng 3g;
The compatibility tonic: substantially just+Radix Codonopsis 9g;
Compatibility diuretic medicine: substantially just+Semen Plantaginis 12g.
Different Chinese medicine compositions to the influence of DN rat mean arterial pressure and renal hemodynamics (
)
| Grouping | n | Mean arterial pressure | Renal blood flow (RPF) | Glomerule was considered rate (GFR) |
| Substantially square | 10 | 15.0±1.0 | 3.92±0.15 | 1.05±0.02 |
| Substantially just+Radix Notoginseng 3g | 8 | 14.8±1.2 | 3.85±0.17 | 1.07±0.01 |
| Substantially just+Radix Codonopsis 9g | 9 | 15.2±0.9 | 3.72±0.19 | 1.06±0.03 |
| Substantially just+Semen Plantaginis 12g | 10 | 14.7±1.4 | 3.82±0.11 | 1.05±0.01 |
Notes: learn by statistics to handle between each group and compare there was no significant difference; But the back three groups the institute at clinical indication slightly the difference.
This result of study not only helps to open up the new treatment approach of primary disease, enriches herbal pharmacology, can also lay good experiment basis for Chinese medicine goes to the world.
The specific embodiment
Embodiment 1, the Chinese medicine composition of treatment diabetic nephropathy, and its composition is: Radix Astragali 30 grams, Radix Aconiti Lateralis Preparata 15 grams, Radix et Rhizoma Rhei (processed) 15 grams.
Embodiment 2, the Chinese medicine composition of treatment diabetic nephropathy, and its composition is: Radix Astragali 45 grams, Radix Aconiti Lateralis Preparata 20 grams, Radix et Rhizoma Rhei (processed) 20 grams.
Embodiment 3, the Chinese medicine composition of treatment diabetic nephropathy, and its composition is: Radix Astragali 15 grams, Radix Aconiti Lateralis Preparata 10 grams, Radix et Rhizoma Rhei (processed) 10 grams.
Embodiment 4, the Chinese medicine composition of treatment diabetic nephropathy, and its composition is: Radix Astragali 40 grams, Radix Aconiti Lateralis Preparata 10 grams, Radix et Rhizoma Rhei (processed) 15 grams.
Embodiment 5, and is substantially the same manner as Example 1, has but increase: Radix Notoginseng 1～1.5g.
Embodiment 6, and is substantially the same manner as Example 1, has but increase: Radix Salviae Miltiorrhizae 4.5～9g.
Embodiment 7, and is substantially the same manner as Example 1, has but increase: Radix Cyathulae 4.5～9g.
Embodiment 8, and is substantially the same manner as Example 1, has but increase: Rhizoma Chuanxiong 5～10g.
Embodiment 9, and is substantially the same manner as Example 1, has but increase: Semen Persicae 4.5～9g.
Embodiment 10, and is substantially the same manner as Example 1, has but increase: Flos Carthami 3～9g.
Embodiment 11, and is substantially the same manner as Example 1, has but increase: Semen Vaccariae 4.5～9g.
Embodiment 12, and is substantially the same manner as Example 1, has but increase: Squama Manis 4.5～9g.
Embodiment 13, and is substantially the same manner as Example 1, has but increase: Herba Lycopi 6～12g.
Embodiment 14, and is substantially the same manner as Example 1, has but increase: Herba Leonuri 9～30g.
Embodiment 15, and is substantially the same manner as Example 1, has but increase: Olibanum 3～6g.
Embodiment 16, and is substantially the same manner as Example 1, has but increase: Myrrha 3～5g.
Embodiment 17, and is substantially the same manner as Example 1, has but increase: Spina Gleditsiae 1.5～5g.
Embodiment 18, and is substantially the same manner as Example 1, has but increase: Rhizoma Curcumae Longae 5～10g.
Embodiment 19, and is substantially the same manner as Example 1, has but increase: Rhizoma Curcumae 4.5～9g.
Embodiment 20, and is substantially the same manner as Example 1, has but increase: rhizoma sparganic 4.5～9g.
Embodiment 21, and is substantially the same manner as Example 1, has but increase: Ramulus Euonymi (Herba Buchnerae cruciatae) 5～10g.
Embodiment 22, and is substantially the same manner as Example 1, has but increase: Radix Ginseng 5～10g.
Embodiment 23, and is substantially the same manner as Example 1, has but increase: Radix Pseudostellariae 6～15g.
Embodiment 24, and is substantially the same manner as Example 1, has but increase: Radix Codonopsis 10～15g.
Embodiment 25, and is substantially the same manner as Example 1, has but increase: Radix Glehniae 10～15g.
Embodiment 26, and is substantially the same manner as Example 1, has but increase: Radix Angelicae Sinensis 6～9g.
Embodiment 27, and is substantially the same manner as Example 1, has but increase: Rhizoma Dioscoreae 15～30g.
Embodiment 28, and is substantially the same manner as Example 1, has but increase: Seem Lablab Album 10～12g.
Embodiment 5, and is substantially the same manner as Example 1, has but increase: Radix Polygoni Multiflori 6～15g.
Embodiment 29, and is substantially the same manner as Example 1, has but increase: the Rhizoma Atractylodis Macrocephalae 5～15g.
Embodiment 30, and is substantially the same manner as Example 1, has but increase: Fructus Lycii 6～12g.
Embodiment 31, and is substantially the same manner as Example 1, has but increase: Rhizoma Polygonati 9～15g.
Embodiment 32, and is substantially the same manner as Example 1, has but increase: Radix Rehmanniae 9～15g.
Embodiment 33, and is substantially the same manner as Example 1, has but increase: Poria 6～12g.
Embodiment 34, and is substantially the same manner as Example 1, has but increase: Rhizoma Smilacis Glabrae 15～60g.
Embodiment 35, and is substantially the same manner as Example 1, has but increase: Caulis Akebiae 3～6g.
Embodiment 36, and is substantially the same manner as Example 1, has but increase: Semen Plantaginis 4.5～15g.
Embodiment 37, and is substantially the same manner as Example 1, has but increase: Pericarpium Arecae 4.5～9g.
Embodiment 38, and is substantially the same manner as Example 1, has but increase: Folium Pyrrosiae 6～12g.
Embodiment 39, and is substantially the same manner as Example 1, has but increase: Semen Abutili 3～9g.
Embodiment 40, and is substantially the same manner as Example 1, has but increase: Semen Coicis 9～30g.
Embodiment 41, and is substantially the same manner as Example 1, has but increase:
Hold 6～15g.
Embodiment 42, and is substantially the same manner as Example 1, has but increase: Polyporus 6～12g.
Embodiment 43, and is substantially the same manner as Example 1, has but increase: Herba Dianthi 4.5～9g.
Claims (5)
1. Chinese medicine composition for the treatment of diabetic nephropathy, the composition of said composition is: Radix Astragali 1 5～45 grams, Radix Aconiti Lateralis Preparata 10～20 grams, Radix et Rhizoma Rhei (processed) 10～20 grams.
2. according to the Chinese medicine composition of the described treatment diabetic nephropathy of claim 1, it is characterized in that the ratio of described each component is: Radix Astragali 30 grams, Radix Aconiti Lateralis Preparata 15 grams, Radix et Rhizoma Rhei (processed) 15 grams.
3. according to the Chinese medicine composition of claim 1 or 2 described treatment diabetic nephropathyes, it is characterized in that also having a kind of in the following medicine in the component: Radix Notoginseng 1～1.5g, Radix Salviae Miltiorrhizae 4.5～9g, Radix Cyathulae 4.5～9g, Rhizoma Chuanxiong 5～10g, Semen Persicae 4.5～9g, Flos Carthami 3～9g, Semen Vaccariae 4.5～9g, Squama Manis 4.5～9g, Herba Lycopi 6～1 2g, Herba Leonuri 9～30g, Olibanum 3～6g, Myrrha 3～5g, Spina Gleditsiae 1.5～5g, Rhizoma Curcumae Longae 5～10g, Rhizoma Curcumae 4.5～9g, rhizoma sparganic 4.5～9g, Ramulus Euonymi (Herba Buchnerae cruciatae) 5～10g.
4. according to the Chinese medicine composition of claim 1 or 2 described treatment diabetic nephropathyes, it is characterized in that also having a kind of in the following medicine in the component: Radix Ginseng 5～10g, Radix Pseudostellariae 6～15g, Radix Codonopsis 10～15g, Radix Adenophorae (Radix Glehniae) 10～15g, Radix Angelicae Sinensis 6～9g, Rhizoma Dioscoreae 15～30g, Seem Lablab Album 10～12g, Radix Polygoni Multiflori 6～15g, the Rhizoma Atractylodis Macrocephalae 5～15g, Fructus Lycii 6～12g, Rhizoma Polygonati 9～15g, Radix Rehmanniae 9～15g.
5. according to the Chinese medicine composition of claim 1 or 2 described treatment diabetic nephropathyes, it is characterized in that also having a kind of in the following medicine in the component: Poria 6～12g, Rhizoma Smilacis Glabrae 15～60g, Caulis Akebiae 3～6g, Semen Plantaginis 4.5～15g, Pericarpium Arecae 4.5～9g, Folium Pyrrosiae 6～12g, Semen Abutili 3～9g, Semen Coicis 9～30g, Herba Polygoni Avicularis 6～15g, Polyporus 6～12g, Herba Dianthi 4.5～9g.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB200410064899XA CN100364601C (en) | 2004-10-10 | 2004-10-10 | Chinese traditional medicine composition for treating diabetic nephropathy |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB200410064899XA CN100364601C (en) | 2004-10-10 | 2004-10-10 | Chinese traditional medicine composition for treating diabetic nephropathy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1634328A CN1634328A (en) | 2005-07-06 |
| CN100364601C true CN100364601C (en) | 2008-01-30 |
Family
ID=34846429
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB200410064899XA Expired - Fee Related CN100364601C (en) | 2004-10-10 | 2004-10-10 | Chinese traditional medicine composition for treating diabetic nephropathy |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100364601C (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100360161C (en) * | 2005-09-23 | 2008-01-09 | 徐忠慧 | Chinese medicine for treating diabets and nephritis |
| CN101785833A (en) * | 2010-04-06 | 2010-07-28 | 马桂玲 | External traditional Chinese medicine compound extract for repairing and treating renal injury and preparation method thereof |
| CN102836329B (en) * | 2012-08-29 | 2014-11-26 | 张定华 | Chinese medicinal composition for treating diabetic nephropathy |
| CN104474394A (en) * | 2014-11-26 | 2015-04-01 | 张治伦 | Renal grafting type medicine prescription for treating diabetic nephropathy |
| CN106139032A (en) * | 2016-08-24 | 2016-11-23 | 冷国玉 | A kind of Chinese medicine composition treating diabetes |
| CN109402127B (en) * | 2018-09-29 | 2021-12-10 | 复旦大学附属眼耳鼻喉科医院 | Group of high-affinity nucleic acid aptamers capable of being specifically bound with connective tissue growth factor and application of high-affinity nucleic acid aptamers |
| CN112121130A (en) * | 2019-10-31 | 2020-12-25 | 福建农林大学 | Traditional Chinese medicine composition for treating/preventing type II diabetes and application thereof |
| CN112220905B (en) * | 2020-11-13 | 2021-12-28 | 广东省中医院（广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院） | Traditional Chinese medicine preparation for treating painful neuropathy caused by diabetes |
| CN113041300B (en) * | 2021-05-20 | 2022-05-10 | 广东省中医院（广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院） | Prescription for treating diabetes and its application |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1370585A (en) * | 2002-03-06 | 2002-09-25 | 黄资源 | Composite Chinese medicine prepn for treating type II diabetes |
-
2004
- 2004-10-10 CN CNB200410064899XA patent/CN100364601C/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1370585A (en) * | 2002-03-06 | 2002-09-25 | 黄资源 | Composite Chinese medicine prepn for treating type II diabetes |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1634328A (en) | 2005-07-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1686529A (en) | Ready prepared Chinese medicine for treating diabetes | |
| CN102178800B (en) | Chinese medicine composition for treating rheumatoid arthritis and preparation method thereof | |
| CN101002906A (en) | Compounding traditional Chinese medicine, and its use | |
| CN102125630B (en) | Traditional Chinese medicinal preparation for treating chronic hepatitis B and preparation method thereof | |
| CN101947300B (en) | Traditional Chinese medicinal composition for treating liver diseases, preparation method thereof and use thereof | |
| CN102397372A (en) | Medicinal composition and pharmaceutical preparation and application thereof to treating irritable bowel syndrome | |
| CN100364601C (en) | Chinese traditional medicine composition for treating diabetic nephropathy | |
| CN102488743B (en) | Chinese traditional medicine composition, preparation method thereof and Chinese traditional medicine preparation | |
| CN102429977B (en) | Medicine for treating diabetes | |
| CN101716252B (en) | Traditional Chinese medicine pill for treating Chronic nephritis and nephrotic syndrome | |
| CN103006989B (en) | Medical composition for treating diabetic nephropathy | |
| CN105267559B (en) | A kind of drug and preparation method thereof for treating diabete peripheral herve pathology | |
| CN101940759B (en) | Chinese medicinal composition for treating liver diseases and preparation method and application thereof | |
| CN1927324A (en) | Preparation method of traditional medicine preparation for treating women's menoxenia | |
| CN1052889C (en) | Chinese proprietary for curing hepatitis | |
| CN101940758B (en) | Traditional Chinese medicinal composition for treating liver diseases, preparation method thereof and application thereof | |
| CN100594921C (en) | Traditional Chinese medicine compound preparations for treating chronic hepatitis B and cirrhosis | |
| CN112933201A (en) | Traditional Chinese medicine composition and traditional Chinese medicine preparation for treating diabetic nephropathy and preparation method thereof | |
| Zhang et al. | Progress in the treatment of chronic glomerulonephritis with traditional Chinese medicine | |
| CN1075727C (en) | Shentong capsule and preparing method thereof | |
| CN100528185C (en) | Chinese medicine capsule for treating AIDS and its preparing method | |
| CN1326555C (en) | Chinese medicinal powder preparation for treating hepatic ascites | |
| CN100415270C (en) | Diabetes treating medicine | |
| CN1401371A (en) | 'Shenhuaxiaokecha' tea and preparing method thereof | |
| CN102233004B (en) | Drug for treating liver diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20080130 Termination date: 20091110 |